Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 5/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.47 |
| ▸ | IGF1R | P08069 | 6/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786704 | 0.82 | PAK4 (0.68) | PAK4PAK1IGF1RHTR2AHTR2C | |
| SCHEMBL802262 | 0.73 | PAK4 (0.56) | PAK4PAK1HTR2A | |
| SCHEMBL786028 | 0.70 | TRPC3 (0.38) | PAK4PAK1IGF1RINSR | |
| SCHEMBL786097 | 0.70 | PAK4 (0.52) | PAK4PAK1HTR2A | |
| SCHEMBL786361 | 0.69 | PAK4 (0.65) | PAK4PAK1HTR2AHTR2C | |
| SCHEMBL786280 | 0.69 | PAK4 (0.51) | PAK4PAK1HTR2A | |
| SCHEMBL27573978 | 0.69 | PAK4 (0.51) | PAK4PAK1HTR2A | |
| SCHEMBL786394 | 0.68 | PAK4 (0.50) | PAK4PAK1HTR2A | |
| SCHEMBL786305 | 0.67 | PAK4 (0.49) | PAK4PAK1HTR2A | |
| SCHEMBL786532 | 0.67 | IGF1R (0.44) | PAK4PAK1IGF1RINSRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100355750-C | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA (US) | 2007-12-19 | — | — | CN | claimed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1317448-B2 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-05-04 | — | — | EP | disclosed |
| CN-1926132-B | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-12-29 | — | — | CN | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-7691853-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-06 | — | — | US | disclosed |
| US-7473691-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-01-06 | — | — | US | disclosed |
| US-6660731-B2 | Alzheimer's disease; anticancer agents; antidiabetic agents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-09 | — | — | US | disclosed |
| US-6638926-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-28 | — | — | US | disclosed |
| US-6613776-B2 | Protein serine/threonine kinase inhibitors used for treating diseases such as cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-6610677-B2 | Enhancing glycogen synthesis, lowering blood levels of glucose, treating colon, ovarian, or breast cancer, treating diabetes, treating schizophrenia | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | PAK4 720/4885PAK1 588/4885IGF1R 520/4885 |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | PAK4 364/4885PAK1 479/4885IGF1R 540/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | PAK4 324/4885PAK1 335/4885IGF1R 346/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PAK4 734/4885PAK1 746/4885IGF1R 477/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | PAK4 973/4885PAK1 702/4885IGF1R 293/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PAK4 466/4885PAK1 465/4885IGF1R 400/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PAK4 412/4885PAK1 568/4885IGF1R 834/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | PAK4 235/4885PAK1 359/4885IGF1R 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.